Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 entities : Humanigen, inc. save search
Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved
Published: 2022-01-05 (Crawled : 12:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: -5.81%
H: 0.0%
C: 0.0%
covid-19 treatment phase 2 phase 2/3 lenzilumab trial covid enroll
First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML)
Published: 2021-10-26 (Crawled : 11:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.61%
H: 0.0%
C: 0.0%
phase 2 lenzilumab leukemia
NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19
Published: 2021-07-30 (Crawled : 16:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: -1.39%
H: 0.0%
C: 0.0%
covid treatment phase 2 phase 2/3 lenzilumab trial
Humanigen’s Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab
Published: 2021-07-22 (Crawled : 15:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.0%
H: 1.65%
C: -0.06%
food phase 1 lenzilumab drug approval phase 2
Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
Published: 2021-04-09 (Crawled : 12:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.53%
H: 2.41%
C: 1.41%
positive results phase 1 positive results phase 3 phase 2 glioblastoma
Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
Published: 2020-12-17 (Crawled : 14:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: -0.26%
H: 26.97%
C: 24.14%
phase 3 phase 1 phase 2 enroll glioblastoma
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.